Diabetes Information

  • Diabetes Educators Slider

    We believe: The greatest solutions arise from collaboration.

    Evidence + Judgment = Best Care

    Start Here

Latest Updates

Canagliflozin (Invokana) now has these indications:

Add-on combination in patients with established cardiovascular disease:   INVOKANA® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). 

Patients with Diabetic Nephropathy:   INVOKANA® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (>33.9 mg/mmol). 

Diabetes Update Sign-Up

Stay up-to-date with diabetes education and management. Receive updates on new medications, products, continuing education for healthcare professionals and more by signing up for our periodic emails.

To view past updates, please visit our archives.